Literature DB >> 20532116

Cognitive Outcomes in the CATIE Schizophrenia Trial: Why do they seem different from previous results?

Philip D Harvey1.   

Abstract

Entities:  

Year:  2007        PMID： 20532116      PMCID： PMC2880938     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN： 1550-5952


× No keyword cloud information.
  11 in total

1.  Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine.

Authors:  Philip D Harvey; Christopher R Bowie; Antony Loebel
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2006       Impact factor: 2.198

Review 2.  Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.

Authors:  P D Harvey; R S Keefe
Journal:  Am J Psychiatry       Date:  2001-02       Impact factor: 18.112

3.  Baseline neurocognitive deficits in the CATIE schizophrenia trial.

Authors:  Richard S E Keefe; Robert M Bilder; Philip D Harvey; Sonia M Davis; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; Del D Miller; Jose M Canive; Lawrence W Adler; Theo C Manschreck; Marvin Swartz; Robert Rosenheck; Diana O Perkins; Trina M Walker; T Scott Stroup; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2006-04-19       Impact factor: 7.853

4.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

5.  Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.

Authors:  Nina Schooler; Jonathan Rabinowitz; Michael Davidson; Robin Emsley; Philip D Harvey; Lili Kopala; Patrick D McGorry; Ilse Van Hove; Marielle Eerdekens; Wim Swyzen; Goedele De Smedt
Journal:  Am J Psychiatry       Date:  2005-05       Impact factor: 18.112

6.  Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.

Authors:  Philip D Harvey; Jonathan Rabinowitz; Marielle Eerdekens; Michael Davidson
Journal:  Am J Psychiatry       Date:  2005-10       Impact factor: 18.112

7.  Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Authors:  Robert M Bilder; Robert S Goldman; Jan Volavka; Pal Czobor; Matthew Hoptman; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Michal Kunz; Miranda Chakos; Thomas B Cooper; Terri L Horowitz; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2002-06       Impact factor: 18.112

8.  Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

Authors:  Robert A Rosenheck; Douglas L Leslie; Jody Sindelar; Edward A Miller; Haiqun Lin; T Scott Stroup; Joseph McEvoy; Sonia M Davis; Richard S E Keefe; Marvin Swartz; Diana O Perkins; John K Hsiao; Jeffrey Lieberman
Journal:  Am J Psychiatry       Date:  2006-12       Impact factor: 18.112

9.  Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.

Authors:  George M Simpson; Ira D Glick; Peter J Weiden; Steven J Romano; Cynthia O Siu
Journal:  Am J Psychiatry       Date:  2004-10       Impact factor: 18.112

10.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Authors:  Richard S E Keefe; Robert M Bilder; Sonia M Davis; Philip D Harvey; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; George Capuano; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Clarence E Davis; John K Hsiao; Jeffrey A Lieberman
Journal:  Arch Gen Psychiatry       Date:  2007-06
View more
  3 in total

Review 1.  Relapse risk assessment in early phase psychosis: the search for a reliable and valid tool.

Authors:  Phil Tibbo; Ashok Malla; Rahul Manchanda; Richard Williams; Ridha Joober
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

Review 2.  Dendritic spine pathology in schizophrenia.

Authors:  J R Glausier; D A Lewis
Journal:  Neuroscience       Date:  2012-04-27       Impact factor: 3.590

3.  Education Mediates Racial Disparities in Cognitive Impairment Among Older Adults With Schizophrenia.

Authors:  Sarah Dobbins; Erin Hubbard; Heather Leutwyler
Journal:  Clin Gerontol       Date:  2021-02-12       Impact factor: 2.871
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.